Profitability
This table compares ZIVO Bioscience and Finch Therapeutics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ZIVO Bioscience | N/A | N/A | -2,240.92% |
| Finch Therapeutics Group | N/A | -69.14% | -26.92% |
Valuation & Earnings
This table compares ZIVO Bioscience and Finch Therapeutics Group”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ZIVO Bioscience | $15,850.00 | 2,478.94 | -$7.78 million | ($2.18) | -4.58 |
| Finch Therapeutics Group | N/A | N/A | -$74.75 million | ($8.82) | -1.56 |
Risk and Volatility
ZIVO Bioscience has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.
Institutional and Insider Ownership
12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ZIVO Bioscience beats Finch Therapeutics Group on 5 of the 9 factors compared between the two stocks.
About ZIVO Bioscience
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
